FROM SINGLE MOLECULES TO CELL REPROGRAMMING: DECIPHERING AND RECODING DISORDERED PIONEER TRANSCRIPTION FACTORS

ERC (European Research Council)HORIZON-ERCID: 101040641
EC Contribution
€15,000
Consortium Size
2 orgs
Start Year
2023
Summary

Pioneer transcription factors (pTFs) have unique capabilities beyond classical TFs: They can invade and open closed chromatin, initiating cell-fate changes. Their remarkable abilities have been used to steer cell-fate decisions and to induce a pluripotent stem cell state through poorly understood pathways. Like most TFs, pTFs consist of structured DNA-binding domains (DBDs) flanked by long intrinsically disordered regions (IDRs). In attempts to explain their pioneering functions, intense focus has been on how the structured DBDs of pTFs interact with the nucleosome core particle. Yet, the critical interactions with nucleosomes beyond the core particle, the interplay between DBDs and IDRs, and the molecular mechanism of chromatin invading and opening, remain unclear.The extensive disorder of pTFs places them outside the scope of current structural biology efforts and understanding their functions therefore requires a different approach. Single-molecule spectroscopy offers a powerful toolbox to monitor dynamic molecular systems and measure their conformational distributions. These methods enable quantitative modeling of distances and dynamics in biomolecules over timescales reaching over 15 orders of magnitude. Building on our recent breakthroughs in single-molecule techniques for studying highly disordered proteins in chromatin regulation and our preliminary data on pTF IDRs, we are in a unique position to apply our expertise to the molecular mechanism of pTFs. Using five established pTFs involved in four distinct cell reprogramming pathways, we intend to: 1) map conformational states, 2) decipher kinetic mechanisms, 3) engineer new pTFs, and 4) observe chromatin remodelling, both in vitro and within the complex cellular environment. A molecular-level understanding of pTF functions may break the barrier to fully controlling cell fate, unleashing the enormous medical potential of cell-based therapy.

Consortium (2)